AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Estrella Immunopharma, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00ZDR7G14
0.99▲ 0.26 (35.53%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.73
Day's Range
0.74 – 1.00
52-Week Range
0.24 – 3.15
Volume
3.6M
Avg Volume
3.4M
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2023-10-02
Share count as of August 11, 2026

Estrella Immunopharma, Inc. Common Stock (ESLA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Estrella Immunopharma, Inc. Common Stock (ESLA)
What is Estrella Immunopharma, Inc. Common Stock's Market Cap?
Estrella Immunopharma, Inc. Common Stock's Market Cap is $42.8M, based on as-reported figures from SEC (XBRL) filings.
What is Estrella Immunopharma, Inc. Common Stock's Enterprise Value?
Estrella Immunopharma, Inc. Common Stock's Enterprise Value is $40.9M, based on as-reported figures from SEC (XBRL) filings.
What is Estrella Immunopharma, Inc. Common Stock's Net Income (TTM)?
Estrella Immunopharma, Inc. Common Stock's Net Income (TTM) is -$13.3M, based on as-reported figures from SEC (XBRL) filings.
What is Estrella Immunopharma, Inc. Common Stock's Diluted EPS (TTM)?
Estrella Immunopharma, Inc. Common Stock's Diluted EPS (TTM) is -0.30, based on as-reported figures from SEC (XBRL) filings.
What is Estrella Immunopharma, Inc. Common Stock's Net Debt?
Estrella Immunopharma, Inc. Common Stock's Net Debt is -$1.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ESLAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Operating expenses
Research and development (including $1,375,000, $4,625,000, $2,750,000 and $6,000,000 from a related party for the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025, respectively)—
General and administrative (including $63,231, $65,151, $133,177 and $129,586 from related parties for the three months ended June 30, 2026 and 2025 and the six months ended June 30, 2026 and 2025, respectively)—
Total operating expenses—
Loss from Operations—
Other expenses:
Change in fair value of derivative liabilities———
Total other expenses———
Loss before income tax—
Income tax provision——
Net loss
Net loss applicable to common stock per share, basic (in Dollars per share)—
Net loss applicable to common stock per share, diluted (in Dollars per share)—